|
End-of-day quote
Shanghai S.E.
28/08/2026
|
5-day change | 1st Jan Change | ||
| 18.15 CNY | +2.43% |
|
+2.77% | +3.01% |
| 08-25 | DaShenLin Pharmaceutical Group Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2026 | CI |
| 04-24 | Dashenlin Pharma's Q1 Profit Rises 11% | MT |
Company Valuation: DaShenLin Pharmaceutical Group Co., Ltd.
Data adjusted to current consolidation scope
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|---|
| Market Cap 1 | 33,307 | 37,585 | 28,359 | 17,151 | 20,066 | 20,670 | - | - |
| Change | - | 12.85% | -24.55% | -39.52% | 17% | 3.01% | - | - |
| Enterprise Value (EV) 1 | 32,838 | 36,233 | 27,369 | 15,778 | 16,831 | 17,330 | 17,271 | 16,492 |
| Change | - | 10.34% | -24.46% | -42.35% | 6.67% | 2.97% | -0.34% | -4.51% |
| P/E | 42.1x | 36.3x | 24.2x | 18.6x | 16.3x | 13.9x | 12x | 10.5x |
| PBR | 6.3x | 6.24x | 4.16x | 2.49x | 2.72x | 2.64x | 2.42x | 2.25x |
| PEG | - | 1.2x | 1.8x | -0.9x | 0.5x | 0.7x | 0.8x | 0.7x |
| Capitalization / Revenue | 1.99x | 1.77x | 1.16x | 0.65x | 0.73x | 0.7x | 0.63x | 0.57x |
| EV / Revenue | 1.96x | 1.71x | 1.12x | 0.6x | 0.61x | 0.58x | 0.53x | 0.46x |
| EV / EBITDA | 13.6x | 19.2x | 12.9x | 4.65x | 4.39x | 4.77x | 4.19x | 3.56x |
| EV / EBIT | 31.6x | 25.5x | 16.8x | 10.5x | 8.26x | 7.48x | 6.52x | 5.45x |
| EV / FCF | 117x | 13.1x | 19.7x | 9.51x | 3.44x | 18.4x | 6.18x | 5.07x |
| FCF Yield | 0.86% | 7.61% | 5.09% | 10.5% | 29.1% | 5.42% | 16.2% | 19.7% |
| Dividend per Share 2 | 0.3472 | 0.5 | 0.31 | 0.31 | 0.49 | 0.9418 | 1.043 | 1.222 |
| Rate of return | 1.19% | 1.52% | 1.24% | 2.06% | 2.78% | 5.19% | 5.75% | 6.73% |
| EPS 2 | 0.6944 | 0.9083 | 1.03 | 0.81 | 1.08 | 1.31 | 1.516 | 1.73 |
| Distribution rate | 50% | 55% | 30.1% | 38.3% | 45.4% | 71.9% | 68.8% | 70.6% |
| Net sales 1 | 16,759 | 21,248 | 24,531 | 26,497 | 27,502 | 29,630 | 32,727 | 36,225 |
| EBITDA 1 | 2,408 | 1,883 | 2,119 | 3,395 | 3,833 | 3,636 | 4,118 | 4,627 |
| EBIT 1 | 1,041 | 1,421 | 1,632 | 1,501 | 2,038 | 2,317 | 2,649 | 3,026 |
| Net income 1 | 791.2 | 1,036 | 1,166 | 914.8 | 1,235 | 1,493 | 1,728 | 1,969 |
| Net Debt 1 | -469.2 | -1,352 | -989.8 | -1,373 | -3,236 | -3,340 | -3,399 | -4,178 |
| Reference price 2 | 29.24 | 33.00 | 24.90 | 15.06 | 17.62 | 18.15 | 18.15 | 18.15 |
| Nbr of stocks (in thousands) | 1,138,968 | 1,138,947 | 1,138,902 | 1,138,848 | 1,138,848 | 1,138,848 | - | - |
| Announcement Date | 27/4/22 | 27/4/23 | 28/4/24 | 25/4/25 | 23/4/26 | - | - | - |
1CNY in Million2CNY
Estimates
P/E, Detailed evolution
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | 13.86x | 0.58x | 4.77x | 5.19% | 3.07B | |
| 16.78x | 0.68x | 10.1x | -.--% | 14.92B | |
| 20.98x | 0.8x | 13.48x | 1.07% | 6.48B | |
| 16.99x | 0.77x | 7.98x | 2.19% | 6.45B | |
| 14.59x | 0.93x | 6.81x | 3.06% | 4.12B | |
| 14.51x | 1.24x | 7.61x | 5.54% | 3.23B | |
| 13.83x | 0.83x | 6.24x | 4.64% | 2.91B | |
| 30.19x | - | - | - | 2.35B | |
| 20.51x | 0.6x | 7.65x | 2% | 1.53B | |
| Average | 18.02x | 0.80x | 8.08x | 2.96% | 5.01B | |
| Weighted average by Cap. | 17.48x | 0.78x | 9.05x | 1.97% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
Year-on-year evolution of the Yield
- Stock Market
- Stocks
- 603233 Stock
- Valuation DaShenLin Pharmaceutical Group Co., Ltd.
Select your edition
All financial news and data tailored to specific country editions
